{"product_id":"alny-ansoff-analysis","title":"(ALNY) Alnylam Pharmaceuticals, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Alnylam Pharmaceuticals, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification to support strategy, investing, or planning. This page displays a real preview of the analysis so you can review style and substance before buying; purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eONPATTRO in hereditary transthyretin-mediated amyloidosis polyneuropathy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eONPATTRO is one of Alnylam’s 3 approved therapies and is already sold in hereditary transthyretin-mediated amyloidosis polyneuropathy, so the Ansoff play is market penetration, not new-market entry. The goal is to win more of the diagnosed adult base in existing markets through specialist adoption, earlier diagnosis, and better persistence in the labeled population.\u003c\/p\u003e\n\u003cp\u003eThat matters because hATTR amyloidosis is rare, with estimated global prevalence around 50,000 people, so growth depends on finding and keeping treated patients, not broadening the disease label. In practice, stronger neurology and cardiology referral pathways can lift starts and refills even without new geography.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGIVLAARI in adult acute hepatic porphyria\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGIVLAARI is already in Alnylam Pharmaceuticals, Inc. commercial portfolio, so growth in adult acute hepatic porphyria depends on deeper use in the current labeled segment. In ENVISION, it cut annualized porphyria attacks by 74% versus placebo, supporting uptake among treated adults who still have attacks or hemin use.\u003c\/p\u003e\n\u003cp\u003eWith AHP remaining ultra-rare, the key lever is finding more eligible adults and converting diagnosed patients to therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOXLUMO in primary hyperoxaluria type 1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOXLUMO, Alnylam Pharmaceuticals, Inc.'s RNAi drug for primary hyperoxaluria type 1 (PH1), already sits in the rare renal franchise, so market penetration means taking more share from the current PH1 pool, not finding a new disease. PH1 is ultra-rare and often diagnosed late, which limits starts. Growth comes from faster testing, more referral to specialist centers, and better treatment persistence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease specialty-center focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. grows in rare disease by winning specialist centers, where hATTR, AHP, and PH1 treatment decisions are made and undiagnosed patients are found. That matters because hATTR affects about 50,000 people worldwide, while PH1 and AHP are ultra-rare, so penetration depends on expert prescribers, referral pathways, and diagnosis rates. In FY2025, this focus supports repeat use in a very small but high-value base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget specialist prescribers first\u003c\/li\u003e\n\u003cli\u003eFind undiagnosed patients fast\u003c\/li\u003e\n\u003cli\u003eBest fit: hATTR, AHP, PH1\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSanofi Genzyme commercialization support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSanofi Genzyme gives Alnylam Pharmaceuticals, Inc. a commercial bridge in existing markets, widening access for approved RNAi medicines and helping convert launch activity into higher uptake. The alliance is part of a broader RNAi development and commercialization tie-up, so market penetration depends less on new geographies and more on deeper reach in the same patient pools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader field force and payer reach\u003c\/li\u003e\n\u003cli\u003eHigher access in current markets\u003c\/li\u003e\n\u003cli\u003eFaster uptake for approved products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor market penetration, the main win is execution: more patients reached, fewer access frictions, and better pull-through for current brands. In practice, this matters most where treatment adoption is still early and each incremental prescription lifts share without needing a new product launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s Growth Hinges on Deeper Rare-Disease Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Alnylam Pharmaceuticals, Inc. means pushing ONPATTRO, GIVLAARI, and OXLUMO deeper into already approved rare-disease pools, not opening new markets. The main levers are faster diagnosis, more specialist referrals, and better persistence in hATTR, AHP, and PH1.\u003c\/p\u003e\n\u003cp\u003eWith hATTR affecting about 50,000 people worldwide and AHP and PH1 remaining ultra-rare, growth comes from converting more diagnosed adults in FY2025. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eONPATTRO\u003c\/td\u003e\n\u003ctd\u003ehATTR\u003c\/td\u003e\n\u003ctd\u003eEarlier diagnosis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGIVLAARI\u003c\/td\u003e\n\u003ctd\u003eAHP\u003c\/td\u003e\n\u003ctd\u003eMore eligible starts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOXLUMO\u003c\/td\u003e\n\u003ctd\u003ePH1\u003c\/td\u003e\n\u003ctd\u003eSpecialist referrals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix overview of Alnylam Pharmaceuticals, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Alnylam Pharmaceuticals Ansoff Matrix for quick growth strategy alignment across pipeline, markets, and expansion options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, regulatory, and industry sources to validate Alnylam growth paths and speed due diligence for Ansoff Matrix decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGivosiran in adolescent acute hepatic porphyria\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGivosiran’s move into adolescent acute hepatic porphyria (AHP) is market development: the drug stays the same, but Alnylam Pharmaceuticals, Inc. expands to a younger patient base. AHP is ultra-rare, with an estimated prevalence of about 1 in 20,000 people in Europe, so even small age-segment gains can matter. This adds pediatric demand to Alnylam Pharmaceuticals, Inc.’s hepatic franchise and widens the addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatisiran in transthyretin amyloidosis with cardiomyopathy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatisiran’s move into transthyretin amyloidosis with cardiomyopathy is classic market development: same RNAi asset, new disease setting. Alnylam’s APOLLO-B data showed patients with ATTR-CM had better functional and quality-of-life outcomes over 12 months, supporting a broader cardiac label path. That expands Onpattro from neurology into cardiology and opens a larger, high-value rare-disease market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOXLUMO expansion beyond PH1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. is pushing OXLUMO beyond its PH1 base into advanced PH1 and recurrent kidney stones, widening the renal addressable market. PH1 is ultra-rare, affecting about 1 in 58,000 live births, while recurrent kidney stones hit roughly 1 in 10 adults, so the move targets a much larger patient pool. This is market development: the same drug, but more eligible patients beyond the original PH1 label.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led ex-U.S. reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. uses partner-led ex-U.S. reach to sell the same RNAi drugs in more countries, so this is market development, not product change. Sanofi Genzyme has helped extend commercialization for medicines like Onpattro and Amvuttra beyond Alnylam's core base. In 2025, this model mattered because it let Alnylam broaden access without rebuilding every local sales force.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame medicines, wider geography\u003c\/li\u003e\n\u003cli\u003ePartners lower launch cost\u003c\/li\u003e\n\u003cli\u003eFaster entry into new markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader rare-disease patient identification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. can grow through market development by finding more diagnosed patients for its 4 approved medicines in new regions and care settings. Its rare-disease franchise is built for underdiagnosed groups, so better screening in cardiology, neurology, and nephrology can add patients without changing the product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 approved medicines support expansion\u003c\/li\u003e\n\u003cli\u003eNew diagnoses drive growth, not reformulation\u003c\/li\u003e\n\u003cli\u003eReferral paths widen in specialty care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam’s 2025 Growth: Same Drugs, Bigger Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. uses market development by pushing the same RNAi drugs into new patients, diseases, and geographies. In 2025, its 4 approved medicines expanded through younger AHP patients, ATTR-CM, broader PH1 use, and partner-led ex-U.S. sales.\u003c\/p\u003e\n\u003cp\u003eThis matters because rare-disease diagnosis is the bottleneck, not the molecule; better screening in cardiology, neurology, and nephrology can lift demand without new product builds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGivosiran\u003c\/td\u003e\n\u003ctd\u003eAdolescent AHP\u003c\/td\u003e\n\u003ctd\u003eSame drug, younger patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatisiran\u003c\/td\u003e\n\u003ctd\u003eATTR-CM\u003c\/td\u003e\n\u003ctd\u003eSame asset, new setting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOXLUMO\u003c\/td\u003e\n\u003ctd\u003eAdvanced PH1, recurrent stones\u003c\/td\u003e\n\u003ctd\u003eSame drug, wider pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eAlnylam Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable Ansoff Matrix for Alnylam Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVutrisiran for ATTR amyloidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVutrisiran is Alnylam Pharmaceuticals, Inc.’s RNAi therapy for ATTR amyloidosis, with AMVUTTRA sales reaching $0.5 billion in 2024, up 77% year over year. That makes it a clear product development move: a new product built for Alnylam Pharmaceuticals, Inc.’s existing amyloidosis base, aimed at deepening share in a market where ATTR-CM affects about 300,000 people worldwide. The 2024 HELIOS-B data also supported broader use in ATTR cardiomyopathy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFitusiran for hemophilia and bleeding disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFitusiran is Alnylam Pharmaceuticals, Inc.'s RNAi therapy for hemophilia A and B and other bleeding disorders, aimed at a large, established hematology market. In 2025, its ATLAS studies showed annualized bleeding rates below 1 in many patients, with dosing as infrequent as once every 2 months. That would expand Alnylam beyond approved rare-disease products into a broader treatment category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInclisiran for hypercholesterolemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInclisiran is a product development move: it brings a new RNAi therapy into the huge, mature hypercholesterolemia market, where about 86 million U.S. adults have total cholesterol of 200 mg\/dL or higher. Leqvio’s twice-yearly dosing helps it stand out in a crowded statin and PCSK9 space. Because the market already exists and the product is new, this fits Ansoff product development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCemdisiran for complement-mediated disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCemdisiran is Alnylam Pharmaceuticals, Inc.’s siRNA program for complement-mediated disorders, so it is a product development play inside an established immune and rare-disease market. Alnylam’s 2024 revenue was about $1.3 billion, and this kind of launch helps expand its RNAi base beyond current franchises. A one-line read: it adds a new therapy class to a known clinical area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew product, same disease space\u003c\/li\u003e\n\u003cli\u003eTargets complement-driven pathology\u003c\/li\u003e\n\u003cli\u003eExtends RNAi into adjacent markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZilebesiran for hypertension\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZilebesiran is a product-development move for Alnylam Pharmaceuticals, Inc. because it targets hypertension, a huge existing market with about 1.3 billion adults worldwide affected. In clinical testing, a single 300 mg dose cut systolic blood pressure by up to 20.3 mmHg at 3 months in early studies, showing a clear shot at a crowded treatment class. If approved, it would compete inside an already served market, not create a new one.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHuge current market: 1.3 billion adults\u003c\/li\u003e\n\u003cli\u003eNew therapy for an existing disease\u003c\/li\u003e\n\u003cli\u003eSingle-dose RNAi profile may aid adherence\u003c\/li\u003e\n\u003cli\u003eDirect fit for product-development strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam Expands RNAi Pipeline Across Big Existing Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc.’s product development is clear: it is pushing new RNAi drugs into existing disease markets. In 2025, fitusiran cut annualized bleeding rates below 1 in many patients, and HELIOS-B kept vutrisiran in the ATTR field. Zilebesiran and cemdisiran do the same in hypertension and complement disease.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003e2025 fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFitusiran\u003c\/td\u003e\n\u003ctd\u003eHemophilia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVutrisiran\u003c\/td\u003e\n\u003ctd\u003eATTR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZilebesiran\u003c\/td\u003e\n\u003ctd\u003eHypertension\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALN-HBV02 for chronic hepatitis B virus infection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALN-HBV02 targets chronic hepatitis B virus infection, a market with about 254 million people living with HBV worldwide and roughly 1.1 million deaths each year. For Alnylam Pharmaceuticals, Inc., that moves the company into a new infectious-disease field with a new product candidate. It is a clear diversification step beyond its approved rare-disease base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALN-HSD for non-alcoholic steatohepatitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALN-HSD targets non-alcoholic steatohepatitis, a new product in a new metabolic liver-disease market, so it fits Alnylam Pharmaceuticals, Inc. diversification. NASH affects about 25% of adults worldwide, and the field has moved fast since the first MASH drug approval in 2024, but it is still an early, high-need space. This expands Alnylam Pharmaceuticals, Inc. beyond rare disease into a much larger commercial market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eALN-AAT02 for AAT deficiency-associated liver disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eALN-AAT02 targets AAT deficiency-associated liver disease, opening a new market outside Alnylam Pharmaceuticals, Inc.’s approved RNAi portfolio. That makes it a clear diversification move in the Ansoff Matrix, because it extends the Company Name into a new disease segment rather than just widening current use. It also deepens Alnylam Pharmaceuticals, Inc.’s liver-disease focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegeneron collaboration for ocular RNAi targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. and Regeneron’s ocular RNAi work is diversification: it moves Alnylam into a new therapy area with a new product set, beyond its 4 approved medicines. The deal adds eye-disease reach to its RNAi platform and broadens the pipeline beyond current indications.\u003c\/p\u003e\n\u003cp\u003eThat matters because ocular targets can open a large adjacent market without building a totally new modality from scratch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew therapeutic area: ophthalmology\u003c\/li\u003e\n\u003cli\u003eNew product set: ocular RNAi targets\u003c\/li\u003e\n\u003cli\u003eExtends beyond 4 approved medicines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegeneron collaboration for CNS RNAi targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc.'s Regeneron collaboration on CNS RNAi targets is a clear diversification move because it pushes both the product set and the addressable market beyond its core commercial base. Central nervous system RNAi could open drug opportunities in disorders where delivery has been a major barrier, expanding Alnylam's reach into a new therapeutic arena.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCNS targets = new market\u003c\/li\u003e\n\u003cli\u003eOutside core commercial base\u003c\/li\u003e\n\u003cli\u003eProduct scope also expands\u003c\/li\u003e\n\u003cli\u003eHigher long-run option value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam Expands Beyond Rare Disease Into Big New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam Pharmaceuticals, Inc. is using diversification to move beyond rare disease and into larger new markets. ALN-HBV02, ALN-HSD, and ALN-AAT02 expand the Company Name into hepatitis B, metabolic liver disease, and AAT deficiency, while the Regeneron eye and CNS RNAi deals add new therapeutic areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003cth\u003eMarket cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV\u003c\/td\u003e\n\u003ctd\u003e254M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH\/MASH\u003c\/td\u003e\n\u003ctd\u003e25% of adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore base\u003c\/td\u003e\n\u003ctd\u003e4 approved medicines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57233975116041,"sku":"alny-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/alny-ansoff-matrix.webp?v=1785710370","url":"https:\/\/dcfanalyst.com\/products\/alny-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}